Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Schwarz M
  • Torre D
  • Lozano-Ojalvo D
  • Tan AT
  • Tabaglio T
  • Mzoughi S
  • Sanchez-Tarjuelo R
  • Le Bert N
  • Lim JME
  • Hatem S
  • Tuballes K
  • Camara C
  • Lopez-Granados E
  • Paz-Artal E
  • Correa-Rocha R
  • Ortiz A
  • Portoles J
  • Cervera I
  • Gonzalez-Perez M
  • Bodega-Mayor I
  • Conde P
  • Oteo-Iglesias J
  • Borobia AM
  • Carcas AJ
  • Frías J
  • Belda-Iniesta C
  • Ho JSY
  • Nunez K
  • Hekmaty S
  • Mohammed K
  • Marsiglia WM
  • Carreño JM
  • Dar AC
  • Berin C
  • Nicoletti G
  • Della Noce I
  • Colombo L
  • Lapucci C
  • Santoro G
  • Ferrari M
  • Nie K
  • Patel M
  • Barcessat V
  • Gnjatic S
  • Harris J
  • Sebra R
  • Merad M
  • Krammer F
  • Kim-Schulze S
  • Marazzi I
  • Bertoletti A
  • Ochando J
  • Guccione E

Abstract

The T cell response to SARS-CoV-2 is detected by a PCR assay on whole blood. Fast, high-throughput methods for measuring the level and duration of protective immune responses to SARS-CoV-2 are needed to anticipate the risk of breakthrough infections. Here we report the development of two quantitative PCR assays for SARS-CoV-2-specific T cell activation. The assays are rapid, internally normalized and probe-based: qTACT requires RNA extraction and dqTACT avoids sample preparation steps. Both assays rely on the quantification of CXCL10 messenger RNA, a chemokine whose expression is strongly correlated with activation of antigen-specific T cells. On restimulation of whole-blood cells with SARS-CoV-2 viral antigens, viral-specific T cells secrete IFN-gamma, which stimulates monocytes to produce CXCL10. CXCL10 mRNA can thus serve as a proxy to quantify cellular immunity. Our assays may allow large-scale monitoring of the magnitude and duration of functional T cell immunity to SARS-CoV-2, thus helping to prioritize revaccination strategies in vulnerable populations.

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Datos de la publicación

ISSN/ISSNe:
1087-0156, 1546-1696

NATURE BIOTECHNOLOGY  Nature Publishing Group

Tipo:
Article
Páginas:
1680-1689

Citas Recibidas en Web of Science: 28

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Compartir